A Phase I Study of Bevacizumab and Escalation Doses of BKM-120 in Patients With Metastatic Renal Cell Carcinoma Who Failed Prior Systemic Therapies.
Phase of Trial: Phase I
Latest Information Update: 29 Sep 2016
At a glance
- Drugs Buparlisib (Primary) ; Bevacizumab
- Indications Renal cancer
- Focus Adverse reactions; Biomarker
- 19 Sep 2016 Status changed from active, no longer recruiting to completed.
- 19 May 2016 Results published in the Cancer
- 16 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.